1.1 	A bill for an act
1.2 	relating to insurance; limiting excessive enrollee cost-sharing on biologic 
1.3 	prescription drugs;proposing coding for new law in Minnesota Statutes, chapter 
1.4 	62Q.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. [62Q.528] BIOLOGIC PRESCRIPTION DRUGS; LIMITATION ON 
1.7 	ENROLLEE COST-SHARING.
1.8 		Subdivision 1.Definitions. (a) For purposes of this section, the terms defined in 
1.9 	this subdivision have the meanings given.
1.10 	(b) "Biologic product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, 
1.11 	blood, blood component or derivative, allergenic product, protein-based peptide-based 
1.12 	product, or analogous product, or arsphenamine or derivative of arsphenamine, or any 
1.13 	other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure 
1.14 	of a disease or condition of human beings.
1.15 	(c) "Enrollee" has the meaning given in section 62Q.01, subdivision 2a.
1.16 	(d) "FDA" means the federal Food and Drug Administration.
1.17 	(e) "Health plan" has the meaning given in section 62Q.01, subdivision 3, but also 
1.18 	includes the coverage described in section 62A.011, subdivision 3, clauses (7) and (10).
1.19 		Subd. 2.Enrollee cost-sharing limited. An enrollee prescribed an FDA-approved 
1.20 	biologic product must not be charged a co-payment, coinsurance, deductible, or other 
1.21 	special payment requirement at a rate that exceeds the co-payment, coinsurance, 
1.22 	deductible, or other special payment requirement assessed the lowest-cost nonpreferred 
1.23 	brand-name FDA-approved medication in the enrollee's health plan's prescription 
1.24 	medication formulary.

2.1 	EFFECTIVE DATE. This section is effective August 1, 2010, and applies to 
2.2 	coverage issued or renewed before, on, or after that date.